Form PTO 1449 U.S. DEPARTMENT OF COMMERCE			ATTY DOCKET NO.		SERIAL NO.			
(Modified)	PATENT AND TRADEMARK OFFICE		283629US0PCT	10/562,486				
			APPLICANT					
LIST OF REFERENCES CITED BY APPLICANT			Haruo SUGIYAMA					
			FILING DATE		GROUP			
			December 27, 2005		1644			
U.S. PATENT DOCUMENTS								
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS			
AA	2007/0082860	04/12/2007	SUGIYAMA, et al.					
AB								
AC								
AD								
AE							•	
AF								
AG							-11.00-	
AH								
Al								
AJ								
AK				-				
AL								
AM				1				
AN								
FOREIGN PATENT DOCUMENTS								
	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO				
AO	03/106682	12/24/2003	WIPO (corresponds to US 2007/008286					
AP								
AQ								
AR								
AS		1						
AT								
AU								
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)								
Akihiro TSUBOI, et al., "Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide								
AV	modified at HLA-A*2402-binding residues", Cancer Immunol Immnother, (2002), Vol. 51 pages 614-620							
AW	Yoshihiro OKA, et al., "Cancer Immunotherapy Targeting Wilms'Tumor Gene WT1 Product ¹ ", The Journal of Immunology, Vol. 164, pages 1873-1880							
AX	Y. MAEDA, et al., "Detection of peptide-specific CTL-precursors in peripheral blood lymphocytes of cancer patients", British Journal of Cancer, (2002) Vol. 87, pages 796-804							
AY	Hideki OHMINAMI, et al., "HLA class I-restricted lysis of leukemia cells by a CD8 ⁺ cytotoxic T-lymphocyte clone specific for WT1 peptide", Blood, January 1, 2002, Vol. 95, No. 1, pages 286-293							
AZ	Akihiro TSUBOI, et al. "Enhanced induction of human WT1-speific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues", (1996), Vol. 274, pages 94-96, XP003016309, (CAPLUS-abstract)							
Examiner					Date Considered			
			t citation is in conformance with MPEP 60 with next communication to applicant.	09; Draw li	ne through	citation	if not in	